FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017578119> ?p ?o ?g. }

• W2017578119 endingPage "1281" @default.
• W2017578119 startingPage "1267" @default.
• W2017578119 abstract "Fibroblasts that have been genetically modified to secrete neurotrophins can stimulate axonal regeneration, rescue injured neurons, and improve function when grafted into a spinal cord injury site. These grafts are usually allografts that require immunosuppression to prevent rejection. In this study, we compared the effects of two immunophilin-ligands (cyclosporine A [CsA] and FK506) that are used clinically to prevent transplant rejection on protection of grafted fibroblasts. As there are risks associated with prolonged immunosuppression, we compared the effects of 2 or 8 weeks of administration of these drugs, in combination with our standard methylprednisolone protocol, in animals that survived for 8 weeks, to determine whether a shorter course of immunosuppression would be effective. Outcome measures included fibroblast survival, infiltration of activated macrophages and microglia into the graft, final lesion size, and growth of host axons into the graft. The graft consisted of a Vitrogen matrix into which fibroblasts were suspended; the graft was placed into a C3/C4 lateral funiculus lesion. The fibroblasts were isolated from a transgenic strain of Fischer rats that produce the marker alkaline phosphatase (Fb/AP). This enabled us to track the grafted fibroblasts and to evaluate the extent of their survival. The grafted matrix filled the lesion cavity. The density of fibroblasts within the matrix differed according to treatment. Fibroblast survival was most robust in animals that received 8 weeks of immunophilin-ligand treatment. FK506 supported greater Fb/AP survival than CsA. ED-1 immunostaining for activated microglia and macrophages showed an inverse correlation between AP immunoreactivity and the density of immune cells within the graft. Thus, prolonged administration of either FK506 or CsA was necessary for maximal fibroblast survival and for limiting the macrophage invasion of the graft. None of the FK506 or CsA protocols modified the size of the lesion, indicating that these immunophilin-ligands had little effect on secondary enlargement of the lesion and therefore little neuroprotective effect. Because immunophilin-ligands have been shown to be neurotrophic, we used RT-97 immunostaining for neurofilaments and calcitonin gene related protein (CGRP) staining for dorsal root axons to visualize axons that grew into the graft. Some axons grew into the matrix even in the absence of immunophilin-ligand treatment, suggesting that the Vitrogen matrix itself is permissive, but all of the immunophilin-ligand protocols were much more effective in eliciting axonal growth. Growth of axons into the transplants was equally increased by drug treatment for 2 or 8 weeks. Thus, both treatments improved fibroblast survival, diminished immune cell invasion, and promoted axonal growth, and a 2-week course of treatment with either immunophilin-ligand was as effective as 8 weeks in stimulating axonal growth." @default.
• W2017578119 created "2016-06-24" @default.
• W2017578119 creator A5017999100 @default.
• W2017578119 creator A5032754159 @default.
• W2017578119 creator A5041601356 @default.
• W2017578119 creator A5050525630 @default.
• W2017578119 creator A5059985761 @default.
• W2017578119 creator A5064377500 @default.
• W2017578119 creator A5079863884 @default.
• W2017578119 date "2005-11-01" @default.
• W2017578119 modified "2023-10-16" @default.
• W2017578119 title "Immunosuppression with Either Cyclosporine A or FK506 Supports Survival of Transplanted Fibroblasts and Promotes Growth of Host Axons into the Transplant after Spinal Cord Injury" @default.
• W2017578119 cites W1518074015 @default.
• W2017578119 cites W1756176550 @default.
• W2017578119 cites W1960585860 @default.
• W2017578119 cites W1973604867 @default.
• W2017578119 cites W1978197119 @default.
• W2017578119 cites W1978559408 @default.
• W2017578119 cites W1980180348 @default.
• W2017578119 cites W1985185792 @default.
• W2017578119 cites W1998919607 @default.
• W2017578119 cites W1999039175 @default.
• W2017578119 cites W2003137746 @default.
• W2017578119 cites W2006405705 @default.
• W2017578119 cites W2007749506 @default.
• W2017578119 cites W2009058877 @default.
• W2017578119 cites W2012534238 @default.
• W2017578119 cites W2025852410 @default.
• W2017578119 cites W2036581091 @default.
• W2017578119 cites W2039721791 @default.
• W2017578119 cites W2042740099 @default.
• W2017578119 cites W2050415048 @default.
• W2017578119 cites W2055269961 @default.
• W2017578119 cites W2058374250 @default.
• W2017578119 cites W2058721062 @default.
• W2017578119 cites W2058963536 @default.
• W2017578119 cites W2072151726 @default.
• W2017578119 cites W2082215172 @default.
• W2017578119 cites W2086762723 @default.
• W2017578119 cites W2087242332 @default.
• W2017578119 cites W2090854960 @default.
• W2017578119 cites W2091021351 @default.
• W2017578119 cites W2094192363 @default.
• W2017578119 cites W2104660263 @default.
• W2017578119 cites W2104748893 @default.
• W2017578119 cites W2111392427 @default.
• W2017578119 cites W2112390736 @default.
• W2017578119 cites W2112408004 @default.
• W2017578119 cites W2113100908 @default.
• W2017578119 cites W2113724937 @default.
• W2017578119 cites W2114969668 @default.
• W2017578119 cites W2129873371 @default.
• W2017578119 cites W2131860899 @default.
• W2017578119 cites W2137341857 @default.
• W2017578119 cites W2147149841 @default.
• W2017578119 cites W2152524281 @default.
• W2017578119 cites W2168655254 @default.
• W2017578119 cites W2171886767 @default.
• W2017578119 cites W2248737114 @default.
• W2017578119 cites W2316920120 @default.
• W2017578119 cites W2419411847 @default.
• W2017578119 cites W4247668468 @default.
• W2017578119 doi "https://doi.org/10.1089/neu.2005.22.1267" @default.
• W2017578119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16305315" @default.
• W2017578119 hasPublicationYear "2005" @default.
• W2017578119 type Work @default.
• W2017578119 sameAs 2017578119 @default.
• W2017578119 citedByCount "38" @default.
• W2017578119 countsByYear W20175781192012 @default.
• W2017578119 countsByYear W20175781192013 @default.
• W2017578119 countsByYear W20175781192015 @default.
• W2017578119 countsByYear W20175781192016 @default.
• W2017578119 countsByYear W20175781192018 @default.
• W2017578119 countsByYear W20175781192019 @default.
• W2017578119 countsByYear W20175781192020 @default.
• W2017578119 countsByYear W20175781192021 @default.
• W2017578119 countsByYear W20175781192022 @default.
• W2017578119 countsByYear W20175781192023 @default.
• W2017578119 crossrefType "journal-article" @default.
• W2017578119 hasAuthorship W2017578119A5017999100 @default.
• W2017578119 hasAuthorship W2017578119A5032754159 @default.
• W2017578119 hasAuthorship W2017578119A5041601356 @default.
• W2017578119 hasAuthorship W2017578119A5050525630 @default.
• W2017578119 hasAuthorship W2017578119A5059985761 @default.
• W2017578119 hasAuthorship W2017578119A5064377500 @default.
• W2017578119 hasAuthorship W2017578119A5079863884 @default.
• W2017578119 hasConcept C118552586 @default.
• W2017578119 hasConcept C141071460 @default.
• W2017578119 hasConcept C142724271 @default.
• W2017578119 hasConcept C202751555 @default.
• W2017578119 hasConcept C203014093 @default.
• W2017578119 hasConcept C2776914184 @default.
• W2017578119 hasConcept C2778334475 @default.
• W2017578119 hasConcept C2779830541 @default.
• W2017578119 hasConcept C2780252810 @default.
• W2017578119 hasConcept C2780381497 @default.
• W2017578119 hasConcept C2780775167 @default.
• W2017578119 hasConcept C2781156865 @default.

• next